- Home
- KINS vs RPID Comparison
KINS vs RPID Comparison
Compare KINS & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KINS
- RPID
- Stock Information
- Founded
- KINS 1886
- RPID 2006
- Country
- KINS United States
- RPID United States
- Employees
- KINS N/A
- RPID N/A
- Industry
- KINS Property-Casualty Insurers
- RPID Medical Specialities
- Sector
- KINS Finance
- RPID Health Care
- Exchange
- KINS Nasdaq
- RPID Nasdaq
- Market Cap
- KINS 189.6M
- RPID 154.7M
- IPO Year
- KINS N/A
- RPID 2021
- Fundamental
- Price
- KINS $15.00
- RPID $2.87
- Analyst Decision
- KINS
- RPID Strong Buy
- Analyst Count
- KINS 0
- RPID 2
- Target Price
- KINS N/A
- RPID $8.00
- AVG Volume (30 Days)
- KINS 118.2K
- RPID 84.4K
- Earning Date
- KINS 11-06-2025
- RPID 11-07-2025
- Dividend Yield
- KINS 1.34%
- RPID N/A
- EPS Growth
- KINS 325.10
- RPID N/A
- EPS
- KINS 2.04
- RPID N/A
- Revenue
- KINS $183,702,376.00
- RPID $30,289,000.00
- Revenue This Year
- KINS $37.94
- RPID $16.63
- Revenue Next Year
- KINS $8.63
- RPID $21.98
- P/E Ratio
- KINS $7.34
- RPID N/A
- Revenue Growth
- KINS 28.36
- RPID 22.57
- 52 Week Low
- KINS $10.45
- RPID $0.87
- 52 Week High
- KINS $22.40
- RPID $4.50
- Technical
- Relative Strength Index (RSI)
- KINS 55.08
- RPID 44.85
- Support Level
- KINS $14.37
- RPID $2.65
- Resistance Level
- KINS $15.09
- RPID $3.12
- Average True Range (ATR)
- KINS 0.47
- RPID 0.20
- MACD
- KINS -0.01
- RPID -0.03
- Stochastic Oscillator
- KINS 53.90
- RPID 37.93
About KINS Kingstone Companies Inc.
Kingstone Companies Inc is a multi-line regional property and casualty insurance holding company. It offers insurance policies to small and mid-sized businesses as well as to individuals.
About RPID Rapid Micro Biosystems Inc.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.